Usana Health Sciences (USNA) EBITDA (2010 - 2026)

Usana Health Sciences (USNA) has reported EBITDA for 17 consecutive years, with -$20.0 million the latest figure, recorded in Q3 2026.

• On a quarterly basis, EBITDA fell 219.61% year-over-year to -$20.0 million in Q3 2026; TTM through Jul 2026 was -$1.1 million, a 101.92% decrease from a year earlier, with the FY2026 full-year figure at $37.4 million, down 43.56% from the prior year.
• EBITDA was -$20.0 million for Q3 2026 at Usana Health Sciences, down from $13.9 million in the prior quarter.
• Over five years, EBITDA peaked at $46.2 million in Q1 2022 and troughed at -$20.0 million in Q3 2026.
• A 5-year average of $18.1 million and a median of $17.8 million in 2024 frame the typical range for EBITDA.
• Across the five-year window, EBITDA grew 7.4% in 2023 and tumbled 219.61% in 2026, its largest moves.
• Over 5 years, EBITDA stood at $22.6 million in 2022, then gained by 7.4% to $24.2 million in 2023, then slumped by 66.1% to $8.2 million in 2024, then tumbled by 85.09% to $1.2 million in 2025, then slumped by 1733.66% to -$20.0 million in 2026.
• The last three EBITDA figures came in at -$20.0 million (Q3 2026), $13.9 million (Q2 2026), and $3.8 million (Q1 2026), per Business Quant data.